Ascitic Fluid Analysis in the Differential Diagnosis of Ascites: Focus on Cirrhotic Ascites

被引:60
作者
Huang, Lin-Lin [1 ]
Xia, Harry Hua-Xiang [2 ]
Zhu, Sen-Lin [1 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastroenterol, 58 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China
[2] Novartis Pharmaceut, E Hanover, NJ USA
基金
中国国家自然科学基金;
关键词
Ascitic fluid analysis; Differential diagnosis; Ascites; Cirrhosis;
D O I
10.14218/JCTH.2013.00010
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Ascites is the pathologic accumulation of fluid within the peritoneal cavity. Because many diseases can cause ascites, in particular cirrhosis, samples of ascitic fluid are commonly analyzed in order to develop a differential diagnosis. The concept of transudate versus exudate, as determined by total protein measurements, is outdated and the use of serumascites albumin gradient as an indicator of portal hypertension is more accurate. Lactate dehydrogenase (LDH), vascular endothelial growth factor (VEGF), and other tumor markers can be helpful in distinguishing between malignant and benign conditions. Glucose and adenosine deaminase levels may support a diagnosis of tuberculous disease, and amylase level may indicate a diagnosis of pancreatitis. Given the specificity and sensitivity of laboratory results, accurate diagnosis should be based on both laboratory data and clinical judgment. (C) 2014 The Second Affiliated Hospital of Chongqing Medical University. Published by XIA & HE Publishing Ltd. All rights reserved.
引用
收藏
页码:58 / 64
页数:7
相关论文
共 93 条
[1]  
Senousy BE, Dragnov PV., Evaluation and management of patients with refractory ascites, World J Gastroenterol, 15, pp. 67-80, (2009)
[2]  
Tarn AC, Lapworth R., Biochemical analysis of ascitic (peritoneal) fluid: what should we measure?, Ann Clin Biochem, 47, pp. 397-407, (2010)
[3]  
Reynolds TB., Ascites, Clin Liver Dis, 4, pp. 151-168, (2000)
[4]  
Biecker E., Diagnosis and therapy of ascites in liver cirrhosis, World J Gastroenterol, 17, pp. 1237-1248, (2011)
[5]  
Planas R, Montoliu S, Balleste B, Rivera M, Miquel M, Masnou H, Et al., Natural history of patients hospitalized for management of cirrhotic ascites, Clin Gastroenterol Hepatol, 4, pp. 1385-1394, (2006)
[6]  
Wimberger P, Gilet H, Gonschior AK, Heiss MM, Moehler M, Oskay-Oezcelik G, Et al., Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone, Ann Oncol, 23, pp. 1979-1985, (2012)
[7]  
Gines P, Cardenas A, Arroyo V, Rodes J., Management of cirrhosis and ascites, N Engl J Med, 350, pp. 1646-1654, (2004)
[8]  
Bendtsen F, Gronbaek H, Hansen JB, Aagaard NK, Schmidt L, Moller S., Treatment of ascites and spontaneous bacterial peritonitis-Part I, Dan Med J, 59, (2012)
[9]  
Moore KP, Wong F, Gines P, Bernardi M, Ochs A, Salerno F, Et al., The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club, Hepatology, 38, pp. 258-266, (2003)
[10]  
Gines P, Cardenas A., The management of ascites and hyponatremia in cirrhosis, Semin Liver Dis, 28, pp. 43-58, (2008)